ABL Bio…has received approval from the Ministry of Food and Drug Safety (MFDS) for a Phase 1 investigational new drug (IND) application for its bispeciﬁc immuno-oncology drug ABL503.

ragistomig (ABL503) - ABL Bio, NovaBridge Biosciences

Jul 28, 2026